Vjhemonc Podcast
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 72:51:50
- More information
Informações:
Synopsis
The video journal of hematological oncology
Episodes
-
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
01/10/2020 Duration: 20minCell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is... The post Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells appeared first on VJHemOnc.
-
SOHO 2020: Next questions in hematological malignancies
25/09/2020 Duration: 17minThe Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated... The post SOHO 2020: Next questions in hematological malignancies appeared first on VJHemOnc.
-
The MPN Sessions: pathobiology, therapeutic strategies & clinical trials
15/09/2020 Duration: 01h01minMyeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell diseases characterized by the excessive production of one or more... The post The MPN Sessions: pathobiology, therapeutic strategies & clinical trials appeared first on VJHemOnc.
-
Latest AML therapies: novel preparations and first in class agents
14/09/2020 Duration: 16minAcute myeloid leukemia (AML) is the most common type of acute leukemia among adults with almost 20,000 new cases reported... The post Latest AML therapies: novel preparations and first in class agents appeared first on VJHemOnc.
-
Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells
10/09/2020 Duration: 10minLymphoma encompasses a wide selection of cancers that progress in the lymphatic system. Broadly, two types of lymphoma exist, non-Hodgkin... The post Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells appeared first on VJHemOnc.
-
CLL: MRD and first-in class agents
13/08/2020 Duration: 12minChronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the... The post CLL: MRD and first-in class agents appeared first on VJHemOnc.
-
The Myeloma Sessions: Evolving management of myeloma & COVID-19
06/08/2020 Duration: 52minPatients with cancer frequently exhibit poorer post-COVID-19 infection outcomes, therefore the management of patients with hematological malignancies remains of high... The post The Myeloma Sessions: Evolving management of myeloma & COVID-19 appeared first on VJHemOnc.
-
MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls
06/08/2020 Duration: 11minIt is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been... The post MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls appeared first on VJHemOnc.
-
The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies
31/07/2020 Duration: 44minA remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of... The post The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies appeared first on VJHemOnc.
-
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation
28/07/2020 Duration: 56minThe ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer... The post The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation appeared first on VJHemOnc.
-
The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
16/07/2020 Duration: 52minThe acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment... The post The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML appeared first on VJHemOnc.
-
Key updates in ALL at EHA 2020
07/07/2020 Duration: 15minAcute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells affecting both adults and children. With a greater... The post Key updates in ALL at EHA 2020 appeared first on VJHemOnc.
-
The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
03/07/2020 Duration: 45minThe multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R)... The post The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients appeared first on VJHemOnc.
-
Systemic mastocytosis: current landscape, novel agents and COVID-19
02/06/2020 Duration: 08minSystemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with... The post Systemic mastocytosis: current landscape, novel agents and COVID-19 appeared first on VJHemOnc.
-
MRD assessment in AML: incorporation into clinical practice
22/04/2020 Duration: 20minAssessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable... The post MRD assessment in AML: incorporation into clinical practice appeared first on VJHemOnc.
-
Myeloma management in the COVID-19 era
14/04/2020 Duration: 10minThe management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians... The post Myeloma management in the COVID-19 era appeared first on VJHemOnc.
-
CAR-T in the CLL space
02/04/2020 Duration: 14minNovel combinations work well for many patients suffering from chronic lymphocytic leukemia (CLL), but there is a subset of patients... The post CAR-T in the CLL space appeared first on VJHemOnc.
-
CAR T-cell therapy & multiple myeloma: past, present & future
02/04/2020 Duration: 11minCAR-T cell therapy offers a potentially paradigm-changing new treatment for multiple myeloma. Additionally, CAR-T toxicity is may be more manageable... The post CAR T-cell therapy & multiple myeloma: past, present & future appeared first on VJHemOnc.
-
Harnessing the tumor microenvironment in lymphoma therapy
02/04/2020 Duration: 11minA deeper understanding of the characteristics, features and interactions at play in the tumor microenvironment has given great insight into... The post Harnessing the tumor microenvironment in lymphoma therapy appeared first on VJHemOnc.
-
CLL therapy: the latest trial updates and innovative novel therapies for the future
20/09/2019 Duration: 25minRecent clinical trials studying novel therapeutic strategies to target chronic lymphocytic leukemia (CLL) have brought a spotlight to their potential... The post CLL therapy: the latest trial updates and innovative novel therapies for the future appeared first on VJHemOnc.